SOURCE: Market Pulse

October 09, 2006 08:40 ET

Market Pulse Breaking News Alert for Monday, October 9, 2006: BIEL - BioElectronics Announces Henry Schein, Inc. Agreement!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA -- (MARKET WIRE) -- October 9, 2006 -- Market Pulse News Alert for this AM, Stocks to Watch are: BioElectronics Corporation (PINKSHEETS: BIEL), Cisco Systems, Inc. (NASDAQ: CSCO), Acorda Therapeutics (NASDAQ: ACOR) and Silver Screen Studios Inc. (OTCBB: SSSU).

Investors need to be watching BioElectronics Corporation (PINKSHEETS: BIEL) this AM! BioElectronics is the developer and marketer of advanced, inexpensive, disposable, drug-free, medical devices, under the trade name ActiPatch Therapy, which are cleared by the U.S. FDA, the European Union and the Canadian regulatory authorities. ActiPatchT is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method designed to reduce swelling, relieve pain and enhance healing of surgical incisions, chronic wounds and orthopedic conditions. The company most recently signed a major distribution agreement with OrthoPro LLC for distribution of the ActiPatchT product. BIEL also recently signed an agreement with Adams BioMedical, Inc., Bremerton, Washington, to establish a national network of independent sales agents and distributors in the podiatry, orthotics and prosthesis markets. More corporate milestones include a sales and distribution agreement with Mentor Corp. for worldwide distribution in plastic surgery and the signing of a retail distribution agreement with Profoot, Inc., a major retail foot care manufacturer, distributor, and Wal-Mart's Vendor of the Year, to internationally market and sell a retail foot care product line. BIEL is developing new products for repetitive stress injuries, such as heel pain, carpel tunnel, back pain, sprains and strains and chronic wounds. BioElectronics has also entered into the sports medicine markets addressing the needs of professional athletes. BIEL has established the use of ActiPatch™ by a number of professional sports teams. The company boasts five unique orthopedic designs aimed at working in conjunction with other therapies team trainers and physicians already provide. BioElectronics is emerging from a development stage company and is ready to capitalize on the potential market for effective therapies which is estimated at $6.5 billion in the U.S. and over $20 billion worldwide. BIEL is poised to become a significant player in the medical devices industry. BIEL just had excellent news out in a press release before today's opening bell announcing that Henry Schein, Inc. the largest provider of healthcare products and services to office-based practitioners in the North American and European markets has agreed to sell and distribute ActiPatch. ActiPatch is a drug-free anti-inflammatory patch! This could be great news for investors!

BioElectronics Corporation (PINKSHEETS: BIEL) today announced that Henry Schein, Inc. the largest provider of healthcare products and services to office-based practitioners in the North American and European markets has agreed to sell and distribute ActiPatch™. ActiPatch is a drug-free anti-inflammatory patch.

BioElectronics President Andrew J. Whelan commented on the agreement, saying, "We believe this distribution agreement creates a powerful relationship that will help us realize our vision of changing the way people heal."

Mr. Whelan continued, "We recognize Schein's distribution channels will play a critical role in accelerating our expansion and growth. Henry Schein's strong and pervasive relationships in the medical professional community, the extensive reach of its more than 600 U.S. sales representatives, and its proven ability to sell innovative high technology products will greatly expand the scope of our markets and the use of ActiPatch. This agreement is a strong endorsement of our technology and its many potential applications in the medical field."

About BioElectronics

BioElectronics Corporation is the maker of ActiPatch™. ActiPatch is a drug-free, anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed electromagnetic therapy for less than a dollar a day. The unique ActiPatch delivery system uses a patented technology to provide a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

About Henry Schein

Henry Schein, a Fortune 500® company, is recognized for its excellent customer service and highly competitive prices. The company's four business groups -- Dental, Medical, International and Technology -- serve more than 500,000 customers worldwide, including dental practices and laboratories, physician practices and veterinary clinics, as well as government and other institutions.

Headquartered in Melville, N.Y., Henry Schein employs nearly 11,000 people with operations in 19 countries and sales of $4.6 billion in 2005. For more information, visit the Henry Schein Web site at www.henryschein.com.

Stocks in the news and acting well as of late include: Cisco Systems, Inc. (NASDAQ: CSCO), Acorda Therapeutics (NASDAQ: ACOR) and Silver Screen Studios Inc. (OTCBB: SSSU).

Information contained herein is the opinion of Market-Pulse.com ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: BioElectronics Corporation compensation from a third party shareholder: five hundred thousand free trading shares of stock in BioElectronics Corporation, already received from a third party shareholder. MP has also been compensated two hundred thousand restricted shares of BioElectronics Corporation by the company. To date, MP has sold two hundred forty thousand shares of stock in BioElectronics Corporation for proceeds totaling seventy eight thousand seven hundred dollars.

MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. Market-Pulse.com and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information